Skip to main content


Left Atrial Appendage Closure Device

WATCHMAN FLX Pro is FDA approved for use in nonvalvular atrial fibrillation patients who are eligible for anticoagulation therapy. Built on the most studied and implanted LAAC device in the world, WATCHMAN FLX Pro is designed to enhance the healing process and optimize the therapy for more patients.

Key Resources




The WATCHMAN FLX™ Pro Device is designed with three first-ever features. The enhanced device features HEMOCOAT™ Technology to improve the healing process, radiopaque markers for precise device placement, and a new 40 mm size for larger appendages.
WATCHMAN FLX Pro device callouts

Coated for Controlled Healing

HEMOCOAT™ Technology is a durable, thromboresistant coating that results in less inflammation and leads to faster, more complete endothelialization.1

Next Level Visibility

Three new radiopaque markers help position and anchor the device with a new level of visual accuracy.

Close with Confidence

A new 40 mm size to treat larger appendages and widest range of anatomies.

1. Saliba et al. JACC: Clinical Electrophysiology, May 2023. Bench testing or pre-clinical study results may not necessarily be indicative of clinical performance. N=12 in a pre-clinical canine study.